Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04507139 · ClinicalTrials.gov registry record
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Active
- Registry status
- 50
- Enrollment target
- 3
- Study locations
NCT04507139: Active study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT04507139 is a study of Parkinson Disease that is active but no longer recruiting, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 50 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04507139, a study of Parkinson Disease, is active but no longer recruiting, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Directly examine whether early (6-month) imaging with DaTscan and \[¹⁸F\] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients.
Primary Outcome
The mean rates of change and the variability around the mean of imaging outcomes in early and Prodromal PD patients, and where appropriate the comparison of these rates between PD patient subsets at study intervals ranging from 6 months to 24 months. Specific examples of outcomes include dopamine transporter striatal uptake and vesicular monoamine transporter type-2 uptake. PD patient subsets may be defined by baseline assessments, genetic mutation, progression milestones and/or rate of clinical
Conditions Studied
Study Locations (3)
Connecticut
- Institute For Neurodegenerative Disorders - New Haven
Massachusetts
- Boston University Medical Center - Boston
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2025-06 |
What the registry record for NCT04507139 still lists
NCT04507139 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04507139 reports a single indexed study location in Connecticut, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04507139 about?
NCT04507139 is a clinical study titled "Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™". Directly examine whether early (6-month) imaging with DaTscan and \[¹⁸F\] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients.
What is the current status of trial NCT04507139?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2020-09-10. Estimated completion is 2025-06.
What conditions does trial NCT04507139 study?
This clinical trial studies the following conditions: Parkinson Disease.
Who is sponsoring clinical trial NCT04507139?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04507139 being conducted?
This trial has 3 study locations across Connecticut, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04507139's enrollment target sits among peer trials
50 155th of 297 higher than 135 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI